Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based Databases

Table 2

Baseline demographics for ineligible patients and eligible patients: insurance claims database.

	Cancer cohort					TKI cohort
	Ineligible patients*		Eligible patients**			Ineligible patients*		Eligible patients**
	(𝑁 = 113,408)		(𝑁 = 6,343)		𝑃 value	(𝑁 = 2,782)		(𝑁=409)		𝑃 value
	𝑁	%	𝑁	%		𝑁	%	𝑁	%
Gender
Male	54,507	48.1	2301	36.3		1,277	45.9	175	42.8
Female	58,874	51.9	4041	63.7	<0.0001	1,503	54.0	234	57.2	0.2326
Age at first cancer or age at start of TKI (years); mean (SD)
	—		57 (10)			—		54 (10)
Insurance type
EPO	8,799	7.8	844	13.3	<0.0001	254	9.1	59	14.4	<0.0001
HMO	19,154	16.9	1,300	20.5		332	11.9	56	13.7
IND	11,206	9.9	58	0.9		304	10.9	2	0.5
OTH	1,179	1.0	1	0		2	0.1	0	0
POS	55,683	49.1	3,551	56.0		1,471	52.9	250	61.1
PPO	17,387	15.3	589	9.3		419	15.1	42	10.3
Cancer type
Breast	37,479	33.0	3,026	47.7	<0.0001	—		—
Cervical	1,567	1.4	49	0.8		—		—
Colorectal	10,305	9.1	773	12.2		—		—
Connective and other soft tissue	1,272	1.1	37	0.6		—		—
Gastric	503	0.4	33	0.5		—		—
Head/neck	3,575	3.2	108	1.7		—		—
Liver	751	0.7	81	1.3		—		—
Lung	5,646	5.0	243	3.8		—		—
Melanoma	12,962	11.4	466	7.3		—		—
Ovarian	2,009	1.8	126	2.0		—		—
Prostate	33,100	29.2	1,145	18.1		—		—
Renal	4,239	3.7	256	4.0		—		—
No. of unique cancers†
One	—		—			709	25.5	92	22.5	0.3656
Two	—		—			1,261	45.3	181	44.3
Three	—		—			601	21.6	101	24.7
Four	—		—			165	5.9	24	5.9
Five	—		—			29	1.0	6	1.5
≥Six	—		—			17	0.6	5	1.2
TKI type
Dasatinib	—		—			26	0.9	1	0.2	0.4876
Erlotinib	—		—			1647	59.2	236	57.7
Gefitinib	—		—			88	3.2	14	3.4
Imatinib	—		—			734	26.4	110	26.9
Lapatinib	—		—			279	10.0	18	11.7
Nilotinib	—		—			8	0.3	—	—
Follow-up time (months); mean (SD)	—		25 (16)			—		14 (12)

∗Ineligible patients did not meet the eligibility requirements for the cohort (see Figures 1 and  2). **Eligible patients had to have a normal baseline LFT value taken ≤30 days of index date and one follow-up LFT after index date. †We are unable to distinguish diagnoses of multiple primaries from metastases in the claims data. EPO: exclusive provider organization; HMO: Health Maintenance Organization; IND: indemnity; OTH: other; POS: point of service; PPO: preferred provider organization; SD: standard deviation; TKI: tyrosine kinase inhibitor.